Kim SH, Lee T, Jang AS, et al. - As per current asthma guidelines, stepping down controller treatment is recommended when the condition is well-controlled for a certain time, but there remains lack of clarity regarding the optimal step-down strategy for well-controlled patients taking a low-dose inhaled corticosteroid (ICS) with a long-acting β ₂ -agonist (LABA), researchers sought to compare two types of step-down approaches for maintaining treatment in this randomized, open-label, three-arm, parallel pragmatic trial. Enrollees were adults suffering from asthma who were aged 18 years or older, and who had been stable with low-dose ICS/LABA for at least 3 months. Participants (n = 225) were randomized to one of three groups (maintaining low-dose ICS/LABA [G1], discontinuing LABA [G2], and decreasing ICS/LABA to once daily [G3]), and were followed for 6 months. An alteration in Asthma Control Test scores between randomization and the final 6-month follow-up, was the primary endpoint. According to findings, both step-down methods were not noninferior to maintenance of treatment. In stable cases, step-down therapy can be tried, but proper monitoring and supervision are important with precautions concerning loss of disease control.